Abeona (ABEO) director 10b5-1 open-market sale of 26,143 shares

Rhea-AI Filing Summary

Abeona Therapeutics director Eric Crombez reported an open-market sale of 26,143 shares of common stock on May 15, 2026 at a weighted average price of $5.5325 per share. The sale was executed under a Rule 10b5-1 trading plan adopted on February 4, 2026, indicating the transactions were pre-arranged. Following this sale, Crombez directly holds 37,313 shares of Abeona Therapeutics common stock.

Insider Trade Summary 10b5-1

Net Seller: 26,143 shares ($144,636)

Net Sell 1 txn

Insider Crombez Eric

Role null

Sold 26,143 shs ($145K)

Type	Security	Shares	Price	Value
Sale	Common Stock	26,143	$5.5325	$145K

Holdings After Transaction: Common Stock — 37,313 shares (Direct, null)

Footnotes (1)

1. The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.44 to $5.66 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Key Figures

Shares sold: 26,143 shares Weighted average sale price: $5.5325 per share Post-transaction holdings: 37,313 shares +2 more

5 metrics

Shares sold 26,143 shares Open-market sale on May 15, 2026

Weighted average sale price $5.5325 per share Common stock sale on May 15, 2026

Post-transaction holdings 37,313 shares Common stock directly owned after sale

Price range of trades $5.44–$5.66 per share Range for multiple sale transactions

Net shares sold 26,143 shares Net-sell direction in transaction summary

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Crombez Eric

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OHIO 44103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/15/2026		S(1)		26,143	D	$5.5325(2)	37,313	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.44 to $5.66 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Eric Crombez	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Abeona Therapeutics (ABEO) report for Eric Crombez?

Abeona Therapeutics director Eric Crombez reported an open-market sale of 26,143 shares of common stock. The transaction occurred on May 15, 2026, and was executed at a weighted average price of $5.5325 per share, according to the Form 4 filing.

At what price did Eric Crombez sell Abeona Therapeutics (ABEO) shares?

Eric Crombez sold Abeona Therapeutics common stock at a weighted average price of $5.5325 per share. The filing notes the shares were sold in multiple trades within a price range from $5.44 to $5.66 per share, all on May 15, 2026.

How many Abeona Therapeutics (ABEO) shares does Eric Crombez hold after the sale?

After the reported sale, Eric Crombez directly holds 37,313 shares of Abeona Therapeutics common stock. This post-transaction ownership reflects his remaining direct position following the open-market sale of 26,143 shares disclosed in the Form 4.

Was Eric Crombez’s Abeona Therapeutics (ABEO) share sale under a trading plan?

Yes. The Form 4 states that the shares were sold under a Rule 10b5-1 trading plan adopted by Eric Crombez on February 4, 2026. Such plans pre-schedule trades, making the timing more routine and less discretionary than ad hoc market transactions.

What does the weighted average price mean in Eric Crombez’s ABEO Form 4?

The weighted average price of $5.5325 per share reflects multiple trades executed between $5.44 and $5.66. The filing explains that the reported price averages these individual sales and that detailed per-trade prices are available upon request from Abeona Therapeutics or the SEC staff.